Leucettine L41 is a novel and potent dual inhibitor of both cdc2-like kinase (CLKs) and DYRKs.

AT7519 (AT-7519; AT 7519) is an orally bioavailable and potent inhibitor of multiple CDKs (cyclin-dependent kinases) with potential antitumor activity.

AT7519 HCl, the hydrochloride salt of AT7519 (AT-7519 ), is a potent, orally bioavailable small molecule CDK inhibitor with potential anticancer activity.

RO-3306 (RO3306; RO 3306) is a novel, potent, ATP-competitive, and selective CDK1 inhibitor with potential antineoplastic activity.

Senexin A is a novel, potent, selective and ATP site competitive inhibitor of CDK8 and CDK19 with Kd values of 0.83 μM and 0.31 μM for CDK8 and CDK19, respectively.

PF-07104091 (PF07104091) is a novel and orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2) with potential anticancer activity.

YKL-5-124 (YKL-5124) is a novel, selective, and covalent CDK7 inhibitor (IC50=53.5 nM) with anticancer activity.

Ribociclib (formerly NVP-LEE011; LEE011; LEE-011; trade name: Kisqali) is a potent, orally bioavailable and highly specific inhibitor of CDK4/6 (cyclin-dependent kinase) with potential antineoplastic activity.

Seliciclib (also known as Roscovitine, CYC 202; CYC-202; CYC202) is a novel, potent, selective and orally bioavailable small-molecule CDK inhibitor with potential anticancer activity.

NU2058 (also known as NU 2058; NU-2058; O6-(Cyclohexylmethyl)guanine) is a novel and potent O(6)-Cyclohexylmethylguanine-based CDK2 (cyclin-dependent kinases 2) inhibitor with IC50 of 17 μM in an enzymatic assay.